Metronomic chemotherapy in head and neck cancer

Francesca De Felice; Ilaria Benevento; Angela Musella; Daniela Musio; Vincenzo Tombolini

doi:10.1016/j.canlet.2016.10.047

Metronomic chemotherapy in head and neck cancer

Cancer Lett. 2017 Aug 1:400:219-222. doi: 10.1016/j.canlet.2016.10.047. Epub 2016 Nov 8.

Authors

Francesca De Felice¹, Ilaria Benevento², Angela Musella³, Daniela Musio², Vincenzo Tombolini⁴

Affiliations

¹ Department of Radiotherapy, Policlinico Umberto I "Sapienza" University of Rome, Viale Regina Elena 326, 00161, Rome, Italy. Electronic address: fradefelice@hotmail.it.
² Department of Radiotherapy, Policlinico Umberto I "Sapienza" University of Rome, Viale Regina Elena 326, 00161, Rome, Italy.
³ Department of Gynecology, Obstetrics and Urological Sciences, "Sapienza" University of Rome, Viale Regina Elena 326, 00161, Rome, Italy.
⁴ Department of Radiotherapy, Policlinico Umberto I "Sapienza" University of Rome, Viale Regina Elena 326, 00161, Rome, Italy; Spencer-Lorillard Foundation, Viale Regina Elena 262, Rome, Italy.

PMID: 27832971
DOI: 10.1016/j.canlet.2016.10.047

Abstract

Head neck cancer (HNC) is generally treated with a multimodality approach. Loco-regional-distant control is often worst, due to the advantage stage disease at diagnosis and the optimal treatment option remains an unresolved issue. Metronomic chemotherapy (MCHT) is an emerging therapeutic option in clinical oncology and it may prove useful in HNC patients.

Keywords: Head neck cancer; Low dose; Metronomic chemotherapy; Recurrence; Survival; Treatment.

Publication types

Review

MeSH terms

Administration, Metronomic
Antineoplastic Agents / administration & dosage*
Evidence-Based Medicine
Head and Neck Neoplasms / drug therapy*
Humans
Randomized Controlled Trials as Topic
Treatment Outcome

Substances

Antineoplastic Agents